selects, invests, and supports promising domestic
and foreign medium and long-term growth companies
that follow global technology trends or demonstrate
high growth potential.
Investment
Yozma Group Korea

Global Network
- Connecting foreign key partners to support overseas commercialization and expansion to Israel, North America, China, Japan and Singapore
- Participate in regular and non-regular networking events
Raising corporate value of a company
- Technical commercialization collaboration and technology application with support from Weizmann Institute of Science
- Incubating growth through acceleration program
Support for attracting investment
- Utilization of Domestic Investors Network
- Attraction of overseas investors for IR
- Yozma’s Plan to Support Investment in Overseas Funds
Our diverse investments span a wide spectrum, including cross-borders investments for globally competitive Korean, Israeli and foreign companies
Main Investment Target
Industries that meet global trends in sectors like biotech, ICT convergence, electricity/electron-related innovations, and edutech, while taking into account technological progress, market size, growth and international expansion potential
Investing Regardless of Stage
Securing outstanding companies and due diligence by experts
Execution of investment
Raising investment payback success rate
Securing outstanding companies and due diligence by experts
Execution of investment
Raising investment payback success rate
Accelerator
Yozma Group Korea
fosters a healthy startup system by discovering startups
with potential and supporting them through processes such as
technology commercialization, investment attraction, overseas expansion, and through eventual exit.
Consultation & Mentorship
Customized accelerator program
Business value and business model improvement
Pitching Skill / Deck Design Mentorship
English and Korean presentation skills lecture
Mentoring
Mock presentations and demos
Investment for Global Expansion
Abroad local workshop
Overseas corporate establishment support
Distribution and ales connections
Joint Ventures, Foreign Investors connections
Advisory
Yozma Group Korea
supports cross-border investment advisory services
for domestic companies aiming for overseas expansion
- Discovering new growth engine
- Attracting foreign investment
- IPO
- M&A
M&A
Industry and Market analysis,
Presenting optimal offers through in-depth financial and strategic analyses
Providing negotiation advice including deal terms and valuations
IPO
Presenting overseas IPO expansion strategy with cross-border listings experts
Providing a systematic solution (deal structuring)
Global
Suggesting international expansion and foreign investment attraction strategies
Providing long-term, big-picture business strategy advice
Tech transfer
Yozma Group Korea


Weizmann Institute of Science
Founded in 1934 by Chaim Weizmann, the first president and chemist of Israel.
One of the World’s Top 5 Institutes of Basic Science along with Max Planck Institute in Germany and Pasteur in France.
2,600 researchers and professors focus on basic science, including computers, mathematics, physics, biology, and chemistry
More than 100 patent technology commercialization per year, 30% of which are technology transfer commercialization
37 billion dollars’ worth of sales of Weizmann Institute-based products
YEDA
YEDA, the technology holding company of the Weizmann Institute of Science,
has many references to blockbuster bio and basic science and technology transfer projects with global companies.
- Copaxone
Development of New Drugs for Multiple Sclerosis
→ Technology transfer to TEVA - Rebif
Development of New Drugs for Multiple Sclerosis
→ Commercialization of technology transferred to Merck - Erbitux
Development of Targeted Anti-Cancer Drugs
→ Commercialization of technology transferred to Merck
- Exelon
New drug development for Alzheimer’s
→ Technology transfer to Norvatis - NDS Ltd.,
Smart Card Technology for Television Set-top Boxes
→ Bought by Cisco - Coloright
A hair color curating service with optical base technology for beauty
→ Acquired by L’Oreal Group
Weizmann Institute and BioLeaders
'P53 Anti-Cancer Drug' Technology Transferred


Novel Cancer Therapy by mutant•p53 Reactivation